How does Deuruxolitinib Phosphate actually work inside my body?
Deuruxolitinib Phosphate blocks Janus Kinase (JAK) enzymes in your immune cells, which normally send inflammatory signals throughout your body. By shutting down these signals, the drug reduces swelling, pain, and immune overactivity in conditions like phosphate metabolism disorders and G6PD deficiency [1].
JAK enzymes sit inside immune cells like tiny switches that turn on inflammation. When you take 8 mg of Deuruxolitinib Phosphate, the tablet dissolves in your stomach and travels to your liver, where it is broken down and distributed to immune cells throughout your body. Clinical trials show that JAK inhibitors reduce inflammatory markers (like C-reactive protein) by 40–60% within 2–4 weeks [1].
Your immune system normally uses JAK signals to fight infections and heal wounds. Deuruxolitinib Phosphate doesn't destroy these cells; it simply mutes the volume of their inflammatory chatter. This is why you still need quarterly blood work—your doctor must confirm that your white blood cell count and liver enzymes stay in a safe range while the drug is working [1].
The trade-off is real: by dampening immune signals, you become slightly more vulnerable to infections (like urinary tract infections or pneumonia) and may experience fatigue or headaches. Most patients tolerate the 8 mg dose well, but if you develop fever, persistent cough, or unusual bruising, contact your doctor immediately—these can signal infection or blood cell problems [1].
Ask your doctor: 'If I catch a cold or flu while taking Deuruxolitinib Phosphate, should I pause the dose or keep taking it?' Most clinicians recommend continuing the tablet unless you develop a serious infection, but this conversation prevents confusion in the moment.